Type I interferon blockade in systemic lupus erythematosus: where do we stand?

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Systemic lupus erythematosus (SLE) is an autoimmune disease marked by a loss of self-tolerance, particularly to chromatin components.
• Autoantibodies against nuclear antigens (ANAs) are a hallmark of SLE.
• Type I interferons (IFNs) are crucial in SLE pathogenesis, promoting the activation of autoreactive T and B cells and autoantibody production.

Purpose of the Study:

• To review the rationale and clinical trial results for IFN-blocking strategies in SLE.
• To discuss the future development of these therapeutic approaches.

Main Methods:

• Review of current clinical trials evaluating IFN-blocking strategies.
• Analysis of therapeutic approaches including monoclonal antibodies against IFN-α and its receptor (IFNAR), and active immunization against IFN-α.

Main Results:

• Multiple IFN-blocking strategies are under clinical investigation for SLE.
• These strategies aim to interrupt the sustained activation of autoreactive cells driven by type I IFNs.

Conclusions:

• IFN-blocking therapies show promise for managing SLE by targeting a key pathogenic pathway.
• Further development of these drugs is warranted to improve treatment outcomes for SLE patients.